Anika Therapeutics, Inc. (ANIK) return on equity (ROE)

Return on equity · fiscal 2025
-7.6%

Anika Therapeutics, Inc. (ANIK) earned a return on equity of -7.6% in fiscal 2025 (the year ended December 31, 2025). That is 29.0 percentage points higher than the -36.6% of fiscal 2024. Figures as of 18 Nov 2026, 12:37 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-7.6%
Change on fiscal 2024
+29.0 pts
Highest on record
21.5%fiscal 2014
Lowest on record
-38.9%fiscal 2023
Fiscal years on record
172009–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Anika Therapeutics, Inc. return on equity (ROE), in more detail

Across the 17 fiscal years on record (2009–2025), the highest was 21.5% in fiscal 2014 and the lowest -38.9% in fiscal 2023. The fiscal 2025 figure is higher than in 19% of the 16 earlier fiscal years on record, whose median is 8.0%.

History · 17 fiscal years

Return on equity by fiscal year

Anika Therapeutics, Inc. return on equity (ROE), year by year

Anika Therapeutics, Inc. (ANIK) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-7.6% 29.0 pts up
2024-36.6% 2.3 pts up
2023-38.9% 33.7 pts down
2022-5.2% 6.6 pts down
20211.4% 10.2 pts up
2020-8.8% 18.2 pts down
20199.4% 2.3 pts up
20187.1% 5.0 pts down
201712.1% 2.5 pts down
201614.6% 0.0 pts
201514.6% 6.9 pts down
201421.5% 6.3 pts up
201315.2% 4.4 pts up
201210.8% 1.9 pts up
20118.9% 3.9 pts up
20105.1% 0.6 pts up
20094.5%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on ANIK

Anika Therapeutics, Inc., figure by figure

Anika Therapeutics, Inc. (ANIK) overview: price, valuation and scorecard

Anika Therapeutics, Inc. return on equity (ROE): questions and answers

What is Anika Therapeutics, Inc.'s return on equity?

Anika Therapeutics, Inc. (ANIK) earned a return on equity of -7.6% in fiscal 2025 (the year ended December 31, 2025). That is 29.0 percentage points higher than the -36.6% of fiscal 2024.

Is Anika Therapeutics, Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 19% of the 16 earlier fiscal years on record, whose median is 8.0%.

What are the highest and lowest return on equity figures on record for Anika Therapeutics, Inc.?

Across the 17 fiscal years on record (2009–2025), the highest was 21.5% in fiscal 2014 and the lowest -38.9% in fiscal 2023.

How is Anika Therapeutics, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative. For Anika Therapeutics, Inc. it is on record here for 17 fiscal years, 2009 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Anika Therapeutics, Inc. (ANIK) return on equity (ROE)”, data as of 18 November 2026. https://funkfolio.com/stock/ANIK/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.